Previous close | 134.13 |
Open | 129.25 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 129.25 - 130.17 |
52-week range | 105.26 - 143.90 |
Volume | |
Avg. volume | 2,603 |
Market cap | 201.697B |
Beta (5Y monthly) | 0.12 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.84 (2.16%) |
Ex-dividend date | 11 Aug 2022 |
1y target est | N/A |
Merck (MRK) is set to make an upfront payment of $150 million to Orna for rights to the latter's circular RNA technology to make vaccines and therapeutics for infectious disease and oncology.
Pharma group alleges breach of non-compete agreement to delay start date of departing business development official
FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza as a combination therapy for patients with metastatic castration-resistant prostate cancer.